<DOC>
	<DOCNO>NCT01279772</DOCNO>
	<brief_summary>In study , investigator propose addition rituximab low risk systemic local relapse patient localized PBL . Patients treat 6 cycle RCHOP-14 RCHOP-21 . The administration radiotherapy follow chemotherapy strongly recommend , base finding retrospective IELSG study , discretion treat center .</brief_summary>
	<brief_title>This Trial Prospective Observational Study Newly Diagnosed Diffuse Large B Cell Primary Breast Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>Previously untreated patient DLBCL breast . Patients must CD20 positive tumor . Stage IE IIE . Must least one objective measurable evaluable disease . Baseline measurement evaluation must obtain within 4 week registration study . Patients must ECOG performance status 02 . Patients must adequate organ function evidence follow laboratory study ( within 2 week prior registration ) : Creatinine Clearance &gt; 50 ml/min Total bilirubin &lt; 2.0 mg/dl AST &lt; 2 x upper limit normal . If document hepatic involvement lymphoma , total bilirubin &lt; 3 x ULN , AST &lt; 5 x ULN . Absolute neutrophil count &gt; 1500/mm3 platelet count &gt; 100,000/mm3 . If document bone marrow involvement lymphoma , absolute neutrophil count &gt; 500/mm3 platelet count &gt; 50,000/mm3 . Patients must age &gt; 18 year . Patients must normal leave ventricular ejection fraction eligible . historical radiographic evidence CNS metastasis include previously treat , resect asymptomatic brain lesion leptomeningeal involvement . pregnant breast feeding patient . Women childbearing potential sexually active male strongly advise use accept effective method contraception . active infection require parental antibiotic . know HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>